El contenido de esta página requiere una versión más reciente de Adobe Flash Player.

Obtener Adobe Flash Player


The activity of Laboratorios Durbán S.A. is focused on the manufacture and marketing of pharmaceutical products, mainly of a very well-known product in the industry: “Tanagel”.

Our products have been on the market for more than 80 years, these days with excellent results at the national level; we are ranked second in the sale of antidiarrheals.

At present time, we are working on an ambitious development plan with the inauguration, in 2002, of our new laboratory that is equipped with state-of-the-art technology, which has allowed us

  • To obtain the Good Manufacturing Practices (GMP) Certification.
  • To include new products in our portfolio.
  • To optimize our production.
  • To manufacture for third parties.
  • To offer, unlike other Laboratories, the option of manufacturing small batches of drugs.

LABORATORIOS FRANCISCO DURBÁN the second company in Andalusia focused on the manufacture of drugs.

Nowadays, the work and market strategies to which we are devoting more time and investment are the expansion of our portfolio of Laboratories that will acquire our drugs and the sale of Tanagel in the international market.

We are currently in the process to register the dossier of Tanagel sachets and capsules in the following countries: Brazil, Argentina, Colombia, Peru, Uruguay, Bolivia, Chile, Costa Rica, El Salvador, Dominican Republic, Panama, Honduras, Guatemala, Nicaragua, Mexico, Venezuela, Ecuador, Thailand, Indonesia, the Philippines, Vietnam, Togo, Chad, Senegal, Ivory Coast, Niger, Mauritania, Mali, Guinea, Benin, Cameroon, Congo, Gabon, Burkina Faso, Algeria, Morocco, Syria, Turkey, Eastern Europe and the whole European Union; with a contract formalized with the company Noventure for the distribution and manufacture at our factory. This marketing process will be accomplished in 2010-2011.

For the international marketing and the national promotion, two clinical studies have been performed on Tanagel: one of them with more than 200 patients (Company Salutis in Barcelona) and another bibliographic review study (Dr. Esteban Carretero. Torrecárdenas Hospital), which have produced very satisfactory results that have been published in the journal of the Spanish Society of Digestive Pathology.

© Durban Laboratorios, 2011 | Legal notice